PRESS RELEASE published on 12/04/2025 at 06:30, 11 months 5 days ago Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region Formycon AG and MS Pharma enter exclusive partnership to commercialize Keytruda biosimilar FYB206 in MENA region, aiming to enhance cancer drug access MENA Region MS Pharma Biosimilar Formycon Keytruda
BRIEF published on 11/24/2025 at 06:35, 11 months 15 days ago Formycon s'associe à NTC pour la commercialisation de biosimilaires en Italie Formycon AG Ophtalmologie FYB203/Baiama® Partenariats En Matière De Biosimilaires Marché Pharmaceutique Italien
BRIEF published on 11/24/2025 at 06:35, 11 months 15 days ago Formycon Partners with NTC for Biosimilar Commercialization in Italy Formycon AG Ophthalmology Biosimilar Partnerships Italy Pharmaceutical Market FYB203/Baiama®
PRESS RELEASE published on 11/24/2025 at 06:30, 11 months 15 days ago NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy Formycon AG partners with NTC for Eylea biosimilar commercialization in Italy. Agreement includes royalties and supply chain organization Italy Formycon AG Commercialization Eylea Biosimilar NTC
BRIEF published on 11/20/2025 at 17:05, 11 months 18 days ago First Berlin réaffirme sa recommandation d'achat sur Formycon AG Formycon AG Dupixent Évaluation D'achat Prévisions De Recettes Biosimilaire De Keytruda
BRIEF published on 11/20/2025 at 17:05, 11 months 18 days ago First Berlin Reaffirms Buy Rating for Formycon AG BUY Rating Formycon AG Revenue Guidance Dupixent Keytruda Biosimilar
PRESS RELEASE published on 11/20/2025 at 17:00, 11 months 18 days ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation on Formycon AG (DE000A1EWVY8) to EUR 53 target price post Q3 results surpassing expectations and upcoming FYB206 study endpoint results First Berlin Equity Research Buy Recommendation Formycon AG FYB206 EUR 53 Target Price
BRIEF published on 11/20/2025 at 06:35, 11 months 19 days ago Lancement en Allemagne du biosimilaire de ranibizumab Epruvy® Formycon AG Ranibizumab Biosimilaire Lancement En Allemagne Soins Ophtalmiques
BRIEF published on 11/20/2025 at 06:35, 11 months 19 days ago Ranibizumab Biosimilar Epruvy® Launched in Germany Formycon AG Ranibizumab Biosimilar Germany Launch Ophthalmic Care
PRESS RELEASE published on 11/20/2025 at 06:30, 11 months 19 days ago Ranibizumab Biosimilar Epruvy® launched in Germany Ranibizumab Biosimilar Epruvy® launched in Germany by Formycon AG, Bioeq AG, and Sandoz AG under license agreement, expanding patient access to treatment options for nAMD and retinopathies Formycon AG Germany Ranibizumab Sandoz AG Epruvy
Published on 11/09/2026 at 13:01, 16 minutes ago CoTec Holdings Corp. Notes HyProMag USA Advances North Texas Rare Earth Magnet Facility With First Major Equipment Delivery
Published on 11/09/2026 at 13:00, 17 minutes ago Nextech3D.ai Closes $720,000 Management-Led Private Placement
Published on 11/09/2026 at 13:00, 17 minutes ago Hillcrest and Equipmake Sign Definitive Agreement to Jointly Develop and License ZVS Inverter Technology for Heavy-Duty Electric Vehicles
Published on 11/09/2026 at 13:00, 17 minutes ago Silver Storm Reports Concentrate Deliveries from La Parrilla
Published on 11/09/2026 at 12:30, 47 minutes ago Tintina Mines Intersects 460m at 0.50% CuEq at the Dos Amigos Copper-Gold Project in Chile
Published on 11/09/2026 at 13:05, 12 minutes ago AUCTION OPENS FOR MICHAEL JACKSON, PRINCESS DIANA & POP CULTURE LEGENDS AS JULIEN'S HEADS TO ABU DHABI
Published on 11/09/2026 at 12:50, 27 minutes ago Shining in Birmingham: Higer New Models Embark on a New Journey in the UK Bus and Coach Market
Published on 11/09/2026 at 12:45, 32 minutes ago SoftwareOne achieves Select partner tier with Anthropic
Published on 11/09/2026 at 10:32, 2 hours 45 minutes ago Disclosure of shares outstanding and voting rights - 09.11.2026
Published on 11/09/2026 at 10:32, 2 hours 45 minutes ago Déclaration nombre d'actions et droits de vote - 09.11.2026
Published on 11/09/2026 at 07:00, 6 hours 17 minutes ago bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Published on 11/09/2026 at 07:00, 6 hours 17 minutes ago BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA
Published on 11/09/2026 at 07:00, 6 hours 17 minutes ago Biophytis annonce le démarrage opérationnel de sa co-entreprise en Chine
